News Headlines

  1. TriLink BioTechnologies And Quantoom Biosciences Sign License And Supply Agreement For CleanCap mRNA Capping Technology 6/3/2025

    TriLink BioTechnologies (TriLink), a Maravai LifeSciences company and global provider of life science reagents and services, has signed a non-exclusive License and Supply Agreement with Quantoom Biosciences, a full-stack RNA partner for mRNA- and saRNA-based vaccines and therapeutics.

  2. Regeneron Expands Clinical-Stage Obesity Portfolio With Strategic In-Licensing Of Novel Dual GLP-1/GIP Receptor Agonist 6/2/2025

    Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced a strategic in-licensing agreement with Hansoh Pharmaceuticals Group Company Limited (“Hansoh”) to acquire exclusive clinical development and commercial rights outside of the Chinese Mainland, Hong Kong and Macau for a dual GLP-1/GIP receptor agonist currently in Phase 3 testing.

  3. STEMCELL Technologies Announces Acquisition Of Cellular Highways 6/2/2025

    STEMCELL Technologies, Canada’s largest biotechnology company, is pleased to announce the acquisition of Cellular Highways Ltd from TTP Group Ltd. Cellular Highways is a biotechnology company based near Cambridge, United Kingdom, that specializes in advanced cell sorting technologies with applications in cell and gene therapy, drug discovery, and general cell research, especially where cells are fragile.

  4. Expansion Of Frontage Laboratories Continues With Launch Of New State-Of-The-Art CRDMO Facility In Exton, PA 6/2/2025

    Frontage Laboratories, Inc. officially unveiled its newest Contract Research, Development and Manufacturing Organization (CRDMO) facility during a grand open house event held on May 22, 2025, at its campus in Exton, Pennsylvania.

  5. Kivu Bioscience Selects Sterling Pharma Solutions For cGMP Manufacturing Of Lead Oncology Antibody-Drug Conjugate KIVU-107 6/2/2025

    Kivu Bioscience, a biotech company developing next-generation antibody-drug conjugates, announced today a manufacturing partnership with Sterling Pharma Solutions, a global contract development and manufacturing organisation, to produce cGMP-quality material for Phase 1 clinical trials of its lead oncology antibody-drug conjugate (ADC) candidate, KIVU-107.

  6. Fujifilm Rebrands Life Sciences Companies To Strengthen Position As Strategic Partners For Life, Offering End-To-End Solutions 6/2/2025

    FUJIFILM Corporation's Life Sciences Group companies, a portfolio of businesses offering products, services and comprehensive solutions that span all stages of therapeutic development from discovery through to commercialization, today announced new names and identities as part of a strategic positioning effort.

  7. Made Scientific Powers Late-Phase And Commercial Cell Therapy Manufacturing With 12,000 sq. ft. Expansion In Princeton, NJ GMP Facility 5/29/2025

    Made Scientific, a leading cell therapy contract development and manufacturing organization (CDMO), today announced a significant expansion of its Princeton, New Jersey facility to meet increasing demand from late-phase and commercial clients and support the anticipated rise in approved advanced therapies.

  8. Cellares And Mitsui Fudosan Announce The First IDMO Smart Factory For Commercial-Scale Cell Therapy Manufacturing In Japan 5/29/2025

    Cellares, a pioneer in automated cell therapy manufacturing, in collaboration with Mitsui Fudosan, announces the establishment of Japan’s first next-gen commercial production site for CAR-T cell therapies.

  9. Bora Adds Automated Fill/Finish Line In Baltimore 5/29/2025

    Bora Pharmaceuticals Co., Ltd., a global leader in pharmaceutical manufacturing, today announced that due to continued growth in demand for its drug product services, it plans to add further sterile fill/finish capacity at its facility in Baltimore, Maryland.

  10. Bionique Testing Laboratories And Cellipont Bioservices Partner To Accelerate Adoption Of Rapid Mycoplasma Testing In Cell And Gene Therapy Manufacturing 5/29/2025

    Bionique Testing Laboratories, a global leader in mycoplasma testing services and part of the Asahi Kasei group, and Cellipont Bioservices, a premier Contract Development and Manufacturing Organization (CDMO) specializing in cell therapies, announce a strategic partnership to advance the adoption and validation of rapid mycoplasma detection methods in support of cGMP manufacturing for cell and gene therapies.